# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Benjamin Franklin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN004-SYN
- Date: 2026-09-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lydia Penhallow, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Gout, stone prevention, kidney, and blood pressure review at about six months. **S**

## History of present illness

Mr. Franklin returns about six months after starting urate-lowering therapy. He had one gout flare, in the left knee ten weeks ago, treated with five days of prednisone; the knee culture grew nothing, and he has had no flare since. The potassium and urate checks planned for two to five weeks after his last visit were not drawn until that sick visit, at seven weeks. He takes allopurinol 300 mg, colchicine 0.6 mg, losartan, atorvastatin, and potassium citrate. His home jug shows about 2.3 L of urine a day. His home blood pressure averages 128/76. He voids well, with nocturia once. He walks 30 minutes most days and has lost 3 kg. **S**

| Element | Detail |
|---|---|
| Interval history | One left knee flare ten weeks ago, crystal-proven and culture-negative; none since |
| Missed checks | Potassium and urate planned for 2 to 5 weeks were drawn at the sick visit at seven weeks |
| Urine output | About 2.3 L a day by measuring jug |
| Home blood pressure | Average 128/76 mmHg |
| Medication tolerance | No rash, diarrhea, muscle aches, or stomach upset from potassium citrate |
| Weight | Down 3 kg since March |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Musculoskeletal | Negative | No joint pain or swelling since the knee flare; no muscle aches |
| Genitourinary | Negative | Good stream, nocturia once, no blood in the urine |
| Gastrointestinal | Negative | No nausea or abdominal pain on potassium citrate |
| Neurological | Negative | No dizziness on standing |

4 systems reviewed. **S**

## Current medications

- Losartan 50 mg oral tablet, one tablet by mouth daily **S**
- Allopurinol 300 mg oral tablet, one tablet by mouth daily **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain, no more than 3 g a day **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**
- Potassium citrate 10 mEq extended-release tablet, one tablet by mouth twice daily with meals **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/76 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 93.2 kg; BMI 30.4 kg/m². All vital signs are synthetic.

Serum urate: 5.4 mg/dL; Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Bicarbonate (total CO2): 26 mmol/L; BUN: 21 mg/dL; Creatinine: 1.32 mg/dL; eGFR: 56 mL/min/1.73 m² (low); Glucose: 97 mg/dL; Urine pH: 6.3 [pH]; Post-void residual volume by bladder ultrasound: 30 mL; IPSS: 5. All results are synthetic.

## Change since baseline

- Serum urate: 9.1 mg/dL (high) at baseline, 5.4 mg/dL at this visit **S**
- Sodium: 140 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Bicarbonate (total CO2): 25 mmol/L at baseline, 26 mmol/L at this visit **S**
- BUN: 22 mg/dL at baseline, 21 mg/dL at this visit **S**
- Creatinine: 1.36 mg/dL (high) at baseline, 1.32 mg/dL at this visit **S**
- eGFR: 54 mL/min/1.73 m² (low) at baseline, 56 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 98 mg/dL at baseline, 97 mg/dL at this visit **S**
- Urine pH: 5.2 [pH] at baseline, 6.3 [pH] at this visit **S**
- IPSS: 16 at baseline, 5 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Joints | No synovitis or tophi; left knee without effusion |
| Cardiovascular | Regular rhythm; no edema; pedal pulses palpable |
| Abdomen | No suprapubic tenderness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Gout at target** (M1A.0710). Serum urate 5.4 mg/dL on allopurinol 300 mg, below the target of 6. The July value of 5.9 was drawn during a flare and was not relied on. Prophylaxis has now run more than six months, with no flare for ten weeks. **S**
   - Continue allopurinol 300 mg daily long term.
   - Stop colchicine today.
   - Serum urate every six months.
   - Flare plan: start prednisone at the first sign and call.
2. **Uric acid stone prevention** (N21.0). Urine pH 6.3, within the 6.0 to 6.5 goal, on potassium citrate; urine output about 2.3 L a day, close to the goal. **S**
   - Continue potassium citrate and fluids.
   - Urine pH with each six-monthly check.
3. **Chronic kidney disease G3a A1** (N18.31). Creatinine 1.32 mg/dL, eGFR 56, potassium 4.6 mmol/L, stable on losartan and potassium citrate. **S**
   - Yearly eGFR, urine albumin-creatinine ratio, hemoglobin, and kidney failure risk in March.
   - Continue atorvastatin.
4. **Hypertension** (I10). 128/76 mmHg in the office and at home, below 130/80. The KDIGO systolic target below 120 was discussed; he prefers not to add a second drug at his age. **S**
   - Continue losartan 50 mg.
5. **Benign prostatic hyperplasia after resection** (N40.1). IPSS 5 and residual 30 mL five months after surgery. **S**
   - Yearly IPSS.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Serum urate | Every 2 to 5 weeks while titrating; every 6 months once at target | Completed today | 5.4 mg/dL on allopurinol 300 mg: at target |
| Laboratory | Serum urate 2 to 5 weeks after raising allopurinol to 300 mg | Once after each dose change | Deferred | Not drawn in the window, a deviation from the protocol; the first value came at the July flare visit at seven weeks (5.9 mg/dL, unreliable during a flare). No change in management resulted, and today's 5.4 confirms the target. Corrective action: the standing order now prints at each visit |
| Laboratory | Potassium 2 to 4 weeks after starting potassium citrate with losartan in chronic kidney disease | Once after starting; then periodically | Deferred | Not drawn in the window, a deviation from the protocol; first checked at the July sick visit at seven weeks (4.7 mmol/L). No harm: potassium 4.6 today. Corrective action: potassium is added to the standing order whenever a potassium-raising drug is started |
| Laboratory | Metabolic panel | Every 6 months on an ARB; with each eGFR draw | Completed today | Potassium 4.6 mmol/L, bicarbonate 26 mmol/L, creatinine 1.32 mg/dL, eGFR 56 |
| Laboratory | Urine pH on alkalinization | With each follow-up on potassium citrate | Completed today | 6.3, within the goal |
| Medication safety | Flare prophylaxis | 3 to 6 months, longer if flares continue | Completed today | Stopped today after more than six months; urate at target and no flare for ten weeks |
| Examination | Office and home blood pressure | Every visit | Completed today | 128/76 mmHg office and home |
| Examination | Peripheral pulses | Every 2 to 3 years at 65 or older | Completed today | Pedal pulses palpable; no claudication |
| Survey | IPSS | Every follow-up; 1, 3, 6, and 12 months after a procedure | Completed today | 5 |
| Examination | Post-void residual | Post-procedural follow-up | Completed today | 30 mL |
| Survey | Three-month post-procedural urologic check | About 3 months after the procedure | Deferred | No separate visit was held at three months, a deviation from the follow-up schedule; urinary symptoms were reviewed and negative at the July sick visit. No harm: IPSS and residual are normal today |
| Laboratory | eGFR, urine albumin-creatinine ratio, hemoglobin, and KFRE | Yearly at G3a A1 | Up to date | Done in March (KFRE 0.2 percent at 2 years and 0.6 percent at 5 years, well below referral thresholds); due again next March |
| Laboratory | Calcium, phosphate, PTH, and vitamin D | Baseline at G3a, then every 6 to 12 months | Due | Normal in March; due next March |
| Laboratory | Lipid panel | Once at CKD diagnosis (KDIGO); yearly in the CMID hypertension schedule | Not indicated | On atorvastatin for kidney disease; KDIGO advises no routine repeat lipid testing |
| Medication safety | Medication review for NSAIDs and drug interactions | Every visit | Completed today | No NSAIDs; colchicine with atorvastatin caused no muscle symptoms, and colchicine stops today |
| Medication safety | Vaccination status | Yearly | Due | Influenza and RSV vaccines planned at next month's wellness visit |
| Self-management | Fluids, diet, alcohol, weight, and activity | Every visit | Completed today | About 2.3 L of urine a day; one glass of wine on most evenings; 3 kg weight loss; walking 30 minutes most days |

## Goal progress

- Serum urate below 6 mg/dL on allopurinol by the six-month review. Outcome by 2026-09-14: Serum urate 5.4 mg/dL on allopurinol 300 mg. **S**
- Bladder stone removed and comfortable voiding with a normal post-void residual. Outcome by 2026-05-18: Stone removed; IPSS from 16 to 6; residual 35 mL. **S**
- No gout flare for six months after starting urate-lowering therapy. Outcome by 2026-09-14: Not met: one knee flare in July while urate was still above target; none since. **S**
- Blood pressure below 130/80 without dizziness. Outcome by 2026-09-14: 128/76 mmHg on losartan. **S**
- Urine output of at least 2.5 L a day and urine pH of 6.0 to 6.5. Outcome by 2026-09-14: Urine pH 6.3 on potassium citrate; home measuring jug shows about 2.3 L a day. **S**

## Medication changes

- Stopped: Colchicine 0.6 mg oral tablet, one tablet by mouth daily for flare prophylaxis **S**

## Guideline basis

- 2020 American College of Rheumatology Guideline for the Management of Gout (2020), American College of Rheumatology (Arthritis Care Res 2020;72(6):744-760)
- Medical Management of Kidney Stones: AUA Guideline (2014, amended 2019), American Urological Association
- EAU Guidelines on Urolithiasis (including bladder stones) (2025), European Association of Urology
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2023 amendment), American Urological Association
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017), American College of Cardiology and American Heart Association (Hypertension 2018;71(6):e13-e115)
- CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, and benign prostatic hyperplasia monographs (2026), Aether Forge

## Follow-up

- Annual wellness visit next month. Serum urate, urine pH, and yearly kidney tests in six months. **S**
- Next scheduled visit 2026-10-19: subsequent annual wellness visit. **S**
